Hjem › Overvægt › Texas › Corpus Christi
Overvægt kliniske forsøg i Corpus Christi, TX
6 studier for Overvægt søger deltagere på steder i og omkring Corpus Christi (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
RekruttererFase 3
- Osvaldo A. Brusco MD, Corpus Christi
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RekruttererFase 3
- Driscoll Children's Hospital, Corpus Christi
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RekruttererFase 3
- Private Practice - Dr. Osvaldo A. Brusco, Corpus Christi
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
RekruttererFase 3
- South Texas Clinical Research, Corpus Christi
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
RekruttererFase 3
- Osvaldo A Brusco MD PA, Corpus Christi
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
RekruttererFase 3
- South Texas Clinical Research, Corpus Christi
Overvægt forsøg i andre byer
- Houston, TX43 studier
- Chicago, IL41 studier
- New York City, NY40 studier
- San Antonio, TX40 studier
- Washington, DC33 studier
- Orlando, FL31 studier
- Dallas, TX30 studier
- Boston, MA28 studier
- Las Vegas, NV27 studier
- Miami, FL27 studier
- Baltimore, MD25 studier
- Jacksonville, FL25 studier
Andre studier i Corpus Christi
- Overvægt5 studier
- Burkitts lymfom4 studier
- Type 2-diabetes4 studier
- Steatotisk leversygdom3 studier
- Akut bifænotypisk leukæmi3 studier
- Akut myeloid leukæmi3 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.